Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' ...

The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the ...

Share of Amgen tumbled on Tuesday after the company's experimental weight-loss drug MariTide failed to meet lofty investor ...

With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...

Shares of weight-loss drugmakers Novo Nordisk and Eli Lilly rose on Tuesday after U.S. President Joe Biden proposed expanding coverage of anti-obesity drugs under state-run health plans and as a ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...

The Biden administration on Tuesday proposed that weight-loss drugs be paid for by Medicaid and Medicare, potentially making ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...